Home > Resources > Whitepapers > Extractables and Leachables Testing in the Pharmaceutical Industry

Extractables and Leachables Testing in the Pharmaceutical Industry

Leachables are organic or inorganic compounds that migrate into the drug product formulation from the container closure system as result of direct contact with the formulation. They are typically low‐molecular weight volatile compounds that migrate through semi‐permeable containers. Leachables testing is required for monitoring and controlling container closure‐ derived impurities in the drug product during stability and/or to qualify container closures for use. Potential sources of leachables include the container fabrication components, migrants from labeling or secondary packaging, and reaction products between the formulation and the container closure system. Leachables can present difficult analytical challenges, as they are frequently present at levels that are orders of magnitude lower than drug degradation products or related substances, well below the sensitivity of the Drug Product testing methods. Therefore, separate analytical methods are usually needed for leachable analysis on the drug product containers.

I'm For Real

Enter your details once to access all our information and resources

 

Spotlight

Chiltern

Chiltern is the leading, global mid-sized contract research organization that listens to client needs to deliver customized clinical development solutions. Chiltern’s team of more than 4,200 works across 47 countries to provide flexible, specialized services, with core competencies in Biopharma, Medical Device and Diagnostics, Oncology, Clinical Analytics and Source. Visit Chiltern.com to learn more about responsive solutions that are Designed Around You®.

OTHER WHITEPAPERS
news image

New technology advances biopharma chromatography productivity

whitePaper | February 16, 2023

Monoclonal antibody drugs (mAbs) make up more than 50 percent of the biologics on the market today, as well as a significant number of new drugs in the development pipeline. The value and impact of these therapies has been dramatic.

Read More
news image

Simcyp™ PBPK for Drug-Drug Interactions (DDI)

whitePaper | July 4, 2023

The past two decades have witnessed transformative changes in our approach to using modeling & simulation to assess and manage DDIs. Multidisciplinary innovations in mechanistic assessment of absorption, distribution, metabolism, and excretion (ADME), population pharmacology and pharmacogenetics.

Read More
news image

High Pressure Homogenizer for Nano-formulation

whitePaper | December 16, 2022

NanoGenizer, a lab-scale microfluidic high pressure homogenizer, utilizes interaction high-pressure microfluidic jet technology, and it is equipped with highly modular power and processing units.

Read More
news image

Seize the digital momentum

whitePaper | January 23, 2023

Investments in biopharmaceutical (biopharma) research and development (R&D) continue to fuel innovation and shape the future of health. However, this year’s analysis demonstrates that despite impressive examples of innovative products the step-change in improved productivity seen in 2021 has not continued.

Read More
news image

The Annual Clinical Trials Round-up 2021

whitePaper | October 13, 2022

In our previous edition of the Clinical Trials Roundup1, we explored the acute disruptions that the COVID-19 pandemic brought to the clinical trials landscape in 2020.

Read More
news image

Ultrasafe film Ultra-high barrier Product stability Patient safety

whitePaper | December 22, 2022

Every viable pharmaceutical packaging system must comprise materials proven to protect its contents against moisture and other atmospheric variables, and be safe for use with the specified dosage form and the route of administration1

Read More

New technology advances biopharma chromatography productivity

whitePaper | February 16, 2023

Monoclonal antibody drugs (mAbs) make up more than 50 percent of the biologics on the market today, as well as a significant number of new drugs in the development pipeline. The value and impact of these therapies has been dramatic.

Read More

Simcyp™ PBPK for Drug-Drug Interactions (DDI)

whitePaper | July 4, 2023

The past two decades have witnessed transformative changes in our approach to using modeling & simulation to assess and manage DDIs. Multidisciplinary innovations in mechanistic assessment of absorption, distribution, metabolism, and excretion (ADME), population pharmacology and pharmacogenetics.

Read More

High Pressure Homogenizer for Nano-formulation

whitePaper | December 16, 2022

NanoGenizer, a lab-scale microfluidic high pressure homogenizer, utilizes interaction high-pressure microfluidic jet technology, and it is equipped with highly modular power and processing units.

Read More

Seize the digital momentum

whitePaper | January 23, 2023

Investments in biopharmaceutical (biopharma) research and development (R&D) continue to fuel innovation and shape the future of health. However, this year’s analysis demonstrates that despite impressive examples of innovative products the step-change in improved productivity seen in 2021 has not continued.

Read More

The Annual Clinical Trials Round-up 2021

whitePaper | October 13, 2022

In our previous edition of the Clinical Trials Roundup1, we explored the acute disruptions that the COVID-19 pandemic brought to the clinical trials landscape in 2020.

Read More

Ultrasafe film Ultra-high barrier Product stability Patient safety

whitePaper | December 22, 2022

Every viable pharmaceutical packaging system must comprise materials proven to protect its contents against moisture and other atmospheric variables, and be safe for use with the specified dosage form and the route of
administration1

Read More
More Whitepapers

Spotlight

Chiltern

Chiltern is the leading, global mid-sized contract research organization that listens to client needs to deliver customized clinical development solutions. Chiltern’s team of more than 4,200 works across 47 countries to provide flexible, specialized services, with core competencies in Biopharma, Medical Device and Diagnostics, Oncology, Clinical Analytics and Source. Visit Chiltern.com to learn more about responsive solutions that are Designed Around You®.

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference